

BRAINSTORM CELL THERAPEUTICS INC
Form 10QSB
August 20, 2007

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 10-QSB

QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED June 30, 2007

TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM _____ TO _____.

COMMISSION FILE NUMBER 333-61610

BRAINSTORM CELL THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

DELAWARE
(State or other jurisdiction of
incorporation or organization)

20-8133057
(I.R.S. Employer
Identification No.)

110 EAST 59th STREET
NEW YORK, NY 10022
(Address of principal executive offices)

(212) 557-9000
(Registrant's telephone number)

Check whether the issuer: (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes No

As of August 15, 2007, the number of shares outstanding of the Registrant's Common Stock, \$0.00005 par value per share, was 32,904,762.

Transitional Small Business Disclosure Format (Check one): Yes No .

TABLE OF CONTENTS

	Page Number
PART I	
Item 1. Financial Statements	4
Item 2. Plan of Operation	27
Item 3. Controls and Procedures	37
PART II	
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	37
Item 5. Other Information	37
Item 6. Exhibits	37

PART I: FINANCIAL INFORMATION

SPECIAL NOTE

Unless otherwise specified in this report, all references to currency, monetary values and dollars set forth herein shall mean United States (U.S.) dollars.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This report contains numerous statements, descriptions, forecasts and projections, regarding Brainstorm Cell Therapeutics Inc. and its potential future business operations and performance. These statements, descriptions, forecasts and projections constitute “forward-looking statements,” and as such involve known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance and achievements to be materially different from any results, levels of activity, performance and achievements expressed or implied by any such “forward-looking statements.” Some of these are described under “Risk Factors” in this report and in our report on Form 10-KSB for the transition period ended December 31, 2006. In some cases you can identify such “forward-looking statements” by the use of words like “may,” “will,” “should,” “could,” “expects,” “hopes,” “anticipates,” “intends,” “plans,” “estimates,” “predicts,” “likely,” “potential,” or “continue” or the negative of any of these terms or similar. These “forward-looking statements” are based on certain assumptions that we have made as of the date hereof. To the extent these assumptions are not valid, the associated “forward-looking statements” and projections will not be correct. Although we believe that the expectations reflected in these “forward-looking statements” are reasonable, we cannot guarantee any future results, levels of activity, performance or achievements. It is routine for our internal projections and expectations to change as the year or each quarter in the year progresses, and therefore it should be clearly understood that the internal projections and beliefs upon which we base our expectations may change prior to the end of each quarter or the year. Although these expectations may change, we may not inform you if they do and we undertake no obligation to do so. We caution investors that our business and financial performance are subject to substantial risks and uncertainties. In evaluating our business, prospective investors should carefully consider the information set forth under the caption “Risk Factors” in addition to the other information set forth herein and elsewhere in our other public filings with the Securities and Exchange Commission.

Item 1. Financial Statements.

BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage Company)

INTERIM CONSOLIDATED FINANCIAL STATEMENTS

AS OF JUNE 30, 2007

IN U.S. DOLLARS IN THOUSANDS

UNAUDITED

INDEX

	Page
Consolidated Balance Sheets	5
Consolidated Statements of Operations	6
Statements of Changes in Stockholders' Equity (Deficiency)	7 - 8
Consolidated Statements of Cash Flows	9
Notes to Consolidated Financial Statements	10 - 26

BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)

CONSOLIDATED BALANCE SHEETS

In U.S. dollars in thousands (except share and per share data)

	June 30, 2007 Unaudited	December 31 2006
ASSETS		
CURRENT ASSETS:		
Cash and cash equivalents	\$ 4	\$ 60
Restricted cash	32	32
Accounts receivable and prepaid expenses	87	42
Total current assets	123	134
LONG-TERM INVESTMENTS:		
Prepaid expenses	8	8
Severance pay fund	45	38
	53	46
PROPERTY AND EQUIPMENT, NET	482	491
OTHER ASSETS, NET	20	52
Total assets	\$ 678	\$ 723
LIABILITIES AND STOCKHOLDERS' DEFICIENCY		
CURRENT LIABILITIES:		
Trade payables	\$ 681	\$ 721
Other accounts payable and accrued expenses	1,111	651
Short-term convertible loans	1,650	937
Short-term loan	206	189
Total current liabilities	3,648	2,498
ACCRUED SEVERANCE PAY	54	41
Total liabilities	\$ 3,702	\$ 2,539
STOCKHOLDERS' DEFICIENCY:		
Stock capital: (Note 7)		
Common stock of \$ 0.00005 par value - Authorized: 800,000,000 shares at June 30, 2007 and December 31, 2006; Issued and outstanding: 25,302,066 and 24,201,812 shares at June 30, 2007 and December 31, 2006, respectively	1	1

Edgar Filing: BRAINSTORM CELL THERAPEUTICS INC - Form 10QSB

Additional paid-in capital	26,095	24,427
Deficit accumulated during the development stage	(29,120)	(26,244)
<u>Total</u> stockholders' deficiency	(3,024)	(1,816)
<u>Total</u> liabilities and stockholders' deficiency	\$ 678	\$ 723

The accompanying notes are an integral part of the consolidated financial statements.

BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)

CONSOLIDATED STATEMENTS OF OPERATIONS

In U.S. dollars in thousands (except share data)

	Six months ended June 30,		Period from September 22, 2000 (inception date) through June 30, 2007
	2007	2006	Unaudited
	Unaudited		Unaudited
Operating costs and expenses:			
Research and development	\$ 618	\$ 443	\$ 2,934
Research and development expenses (income) related to stocks, warrants and options granted to employees and service providers	378	(537)	16,001
General and administrative	339	352	2,230
General and administrative expenses related to stocks, warrants and options granted to employees and service providers	866	1,217	6,045
Total operating costs and expenses	2,201	1,475	27,210
Financial expenses, net	664	64	1,681
	2,865	1,539	28,891
Taxes on income	11	16	65
Loss from continuing operations	2,876	1,555	28,956
Net loss from discontinued operations	-	-	164
Net loss	\$ 2,876	\$ 1,555	\$ 29,120
Basic and diluted net loss per share from continuing operations	\$ 0.12	\$ 0.07	
Weighted average number of shares outstanding used in computing basic and diluted net loss per share	24,596,881	22,909,615	

The accompanying notes are an integral part of the consolidated financial statements.

BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)

STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY)

In U.S. dollars in thousands (except share data)

	Common stock		Additional paid-in capital	Deferred stock-based compensation	Deficit accumulated during the development stage	Total stockholders' equity(deficiency)
	Number	Amount				
Balance as of September 22, 2000 (date of inception)	-	\$ -	\$ -	\$ -	\$ -	-
Stock issued on September 22, 2000 for cash at \$ 0.00188 per stock	8,500,000	1	15	-	-	16
Stock issued on March 31, 2001 for cash at \$ 0.0375 per stock	1,600,000	-	60	-	-	60
Contribution of capital	-	-	8	-	-	8
Net loss	-	-	-	-	(17)	(17)
Balance as of March 31, 2001	10,100,000	1	83	-	(17)	67
Contribution of capital	-	-	11	-	-	11
Net loss	-	-	-	-	(26)	(26)
Balance as of March 31, 2002	10,100,000	1	94	-	(43)	52
Contribution of capital	-	-	15	-	-	15
Net loss	-	-	-	-	(47)	(47)
Balance as of March 31, 2003	10,100,000	1	109	-	(90)	20
2-for-1 stock split	10,100,000	-	-	-	-	-
Stock issued on August 31, 2003 to purchase mineral option at \$ 0.065 per stock	100,000	-	6	-	-	6
Cancellation of stocks granted to Company's	(10,062,000)	(1)	1	-	-	-

Edgar Filing: BRAINSTORM CELL THERAPEUTICS INC - Form 10QSB

President

Contribution of capital	-	-	15	-	-	15
Net loss	-	-	-	-	(73)	(73)
Balance as of March 31, 2004	10,238,000	-	131	-	(163)	(32)
Stock issued on June 24, 2004 for private placement at \$ 0.01 per stock, net of \$ 25,000 issuance expenses (Note 7c(1)(a))	8,510,000	1	60	-	-	61
Contribution of capital (Note 7b)	-	-	7	-	-	7
Stock issued in 2004 for private placement at \$ 0.75 per unit (Note 7c(1)(a))	1,894,808	-	1,418	-	-	1,418
Cancellation of stocks granted to service providers	(1,800,000)	-	-	-	-	-
Deferred stock-based compensation related to options granted to employees	-	-	5,979	(5,979)	-	-
Amortization of deferred stock-based compensation related to stocks and options granted to employees (Note 7c(2))	-	-	-	584	-	584
Compensation related to stocks and options granted to service providers (Note 7c(3)(c))	2,025,000	-	17,506	-	-	17,506
Net loss	-	-	-	-	(18,840)	(18,840)
Balance as of March 31, 2005	20,867,808	1	25,101	(5,395)	(19,003)	704

The accompanying notes are an integral part of the consolidated financial statements.

BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)

STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY)

In U.S. dollars in thousands (except share data)

	Common stock		Additional paid-in capital	Deferred stock-based compensation	Deficit accumulated during the development stage	Total stockholders' equity (deficiency)
	Number	Amount				
Balance as of March 31, 2005	20,867,808	1 \$	25,101 \$	(5,395) \$	(19,003) \$	704
Stock issued on May 12, 2005 for private placement at \$ 0.8 per stock (Note 7c(1)(d))	186,875		149	-	-	149
Stock issued on July 27, 2005 for private placement at \$ 0.6 per stock (Note 7c(1)(e))	165,000		99	-	-	99
Stock issued on September 30, 2005 for private placement at \$0.8 per share (Note 7c(1)(f))	312,500		225	-	-	225
Stock issued on December 07, 2005 for private placement at \$0.8 per share (Note 7c(1)(f))	187,500		135	-	-	135
Forfeiture of options granted to employees	-	-	(3,363)	3,363	-	-
Deferred stock-based compensation related to stocks and options granted to directors and employees	200,000		486	(486)	-	-
Amortization of deferred stock-based compensation related	-	-	51	1,123	-	1,174

to options and stocks granted to employees and directors (Note 7c(2))							
Stock-based compensation related to options and stocks granted to service providers (Note 7c(3)(c))	934,904		662	-	-		662
Reclassification due to application of EITF 00-19			(7,906)				(7,906)
Beneficial conversion feature related to a convertible bridge loan	-	-	164	-	-		164
Net loss	-	-	-	-	(3,317)		(3,317)
Balance as of March 31, 2006	22,854,587	1	15,803	(1,395)	(22,320)		(7,911)
Elimination of deferred stock compensation due to implementation of FAS 123(R)	-	-	(1,395)	1,395	-		-
Stock-based compensation related to stocks and options granted to directors and employees	200,000		1,168	-	-		1,168
Reclassification due to application of EITF 00-19	-	-	7,191	-	-		7,191
Stock-based compensation related to options and stocks granted to service providers (Note 7c)	1,147,225		453	-	-		453
Warrants issued to convertible note holder	-	-	11	-	-		11
Warrants issued to loan holder	-	-	110	-	-		110
Beneficial conversion feature related to convertible bridge loans	-	-	1,086	-	-		1,086

Edgar Filing: BRAINSTORM CELL THERAPEUTICS INC - Form 10QSB

Net loss	-	-	-	-	(3,924)	(3,924)
Balance as of December 31, 2006	24,201,812	1	24,427	-	(26,244)	(1,816)
Stock-based compensation related to options and stocks granted to service providers (Note 7b)	464,095	-	714	-	-	714
Warrants issued to convertible note holder (Note 6)	-	-	84	-	-	84
Stock-based compensation related to stocks and options granted to directors and employees	200,000	-	530	-	-	530
Beneficial conversion feature related to convertible bridge loans (Note 6)	-	-	252	-	-	252
Conversion of convertible loans	436,159	-	88	-	-	88
Net loss	-	-	-	-	(2,876)	(2,876)
Balance as of June 30, 2007 (unaudited)	25,302,066	1 \$	26,095 \$	- \$	(29,120) \$	(3,024)

The accompanying notes are an integral part of the consolidated financial statements.

BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)

CONSOLIDATED STATEMENTS OF CASH FLOWS

In U.S. dollars in thousands

	Six months ended		Period from
	June 30,		September 22,
	2007	2006	2000 (inception
	Unaudited		date) through
			June 30,
			2007
			Unaudited
<u>Cash flows from operating activities:</u>			
Net loss	\$ (2,876)	\$ (1,555)	\$ (29,120)
Less - loss for the period from discontinued operations	-	-	164
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:			
Depreciation	93	35	298
Erosion of restricted cash	-	(2)	-
Accrued severance pay, net	6	4	9
Accrued interest on loans	104	75	184
Amortization of discount on short-term loans	502	103	1,353
Change in fair value of options and warrants	-	(795)	(795)
Expenses related to stocks and options granted to service providers	714	657	19,401
Amortization of deferred stock-based compensation related to options granted to employees and directors	530	738	3,455
Increase in accounts receivable and prepaid expenses	(45)	(41)	(86)
Increase (decrease) in trade payables	(40)	140	680
Increase (decrease) in other accounts payable and accrued expenses	460	(151)	1,106
Net cash used in continuing operating activities	(552)	(792)	(3,351)
Net cash used in discontinued operating activities	-	-	(23)
Total net cash used in operating activities (Note 1g)	(552)	(792)	(3,374)
<u>Cash flows from investing activities:</u>			
Purchase of property and equipment	(39)	(104)	(618)
Restricted cash	-	-	(32)
Investment in lease deposit	-	1	(8)
Net cash used in continuing investing activities	(39)	(103)	(658)
Net cash used in discontinued investing activities	-	-	(16)
Total net cash used in investing activities	(39)	(103)	(674)

Cash flows from financing activities:

Proceeds from issuance of Common stock and warrants, net	-	-	2,087
Proceeds from loans, notes and issuance of warrants, net	535	1,098	1,922
Net cash provided by continuing financing activities	535	1,098	4,009
Net cash provided by discontinued financing activities	-	-	43
Total net cash provided by financing activities	535	1,098	4,052
Increase (decrease) in cash and cash equivalents	(56)	203	4
Cash and cash equivalents at the beginning of the period	60	289	-
Cash and cash equivalents at end of the period	\$ 4	\$ 492	\$ 4

The accompanying notes are an integral part of the consolidated financial statements.

**BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)**

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

In U.S. dollars in thousands (except share data)

NOTE 1:-

GENERAL

- a. Brainstorm Cell Therapeutics Inc. (formerly: Golden Hand Resources Inc.) ("the Company") was incorporated in the State of Washington on September 22, 2000.
- b. On May 21, 2004, the former major stockholders of the Company entered into a purchase agreement with a group of private investors, who purchased from the former major stockholders 6,880,000 shares of the then issued and outstanding 10,238,000 shares of the Company's Common stock.
- c. On July 8, 2004, the Company entered into a licensing agreement with Ramot of Tel Aviv University Ltd. ("Ramot"), an Israeli corporation, to acquire certain stem cell technology (see Note 3 to the financial statements as of December 31, 2006). Subsequent to this agreement, the Company decided to focus on the development of novel cell therapies for neurodegenerative diseases, particularly, Parkinson's disease, based on the acquired technology and research to be conducted and funded by the Company.

Following the licensing agreement dated July 8, 2004, the management of the Company has decided to abandon all old activities related to the sale of the digital data recorder product. The discontinuation of this activity was accounted for under the provision of SFAS 144, "Accounting for the Impairment or Disposal of Long-Lived Assets".

- d. On November 22, 2004, the Company changed its name from Golden Hand Resources Inc. to Brainstorm Cell Therapeutics Inc. to better reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases.
- e. On October 25, 2004, the Company formed a wholly-owned subsidiary in Israel, Brainstorm Cell Therapeutics Ltd. ("BCT").
 - f. On December 21 2006, the Company changed its state of incorporation from Washington to Delaware.
 - g. As of June 30, 2007, the Company had accumulated deficit of \$ 29,120, working capital deficiency of \$ 3,525, incurred net loss of \$ 2,876 and negative cash flows from operating activities in the amount of \$ 552 for the six months ended June 30, 2007. In addition, the Company has not yet generated any revenues.

These conditions raise substantial doubt as to the Company's ability to continue to operate as a going concern.

The Company's ability to continue to operate as a going concern is dependent upon additional financial support.

These financial statements do not include any adjustments relating to the recoverability and classification of assets' carrying amounts or the amount and classification of liabilities that may be required should the Company be unable to continue as a going concern.

**BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)**

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

In U.S. dollars in thousands (except share data)

NOTE 1:- GENERAL (Cont.)

The Company intends to raise additional capital to fund its operations. In the event the Company is unable to successfully raise capital and generate revenues, it is unlikely that the Company will have sufficient cash flows and liquidity to finance its business operations as currently contemplated and might not be able to pay its liabilities on their scheduled maturity dates.

Accordingly, the Company will likely reduce general and administrative expenses and cease or delay the development project until it is able to obtain sufficient financing. There can be no assurance that sufficient revenues will be generated and that additional funds will be available on terms acceptable to the Company, or at all.

h. On September 17, 2006, the Board of Directors of the Company determined to change the Company's fiscal year-end from March 31 to December 31.

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES

The significant accounting policies applied in the annual financial statements of the Company as of December 31, 2006, are applied consistently in these financial statements.

NOTE 3:- UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

The accompanying unaudited interim financial statements have been prepared in a condensed format and include the consolidated financial operations of the Company and its fully owned subsidiary as of June 30, 2007 and for the six months then ended, in accordance with accounting principles generally accepted in the United States relating to the preparation of financial statements for interim periods. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the six months ended June 30, 2007 are not necessarily indicative of the results that may be expected for the year ended December 31, 2007.

NOTE 4:- RESEARCH AND LICENSE AGREEMENT

The Company's total obligation to Ramot as of June 30, 2007, was \$ 513 (see Note 8e).

NOTE 5:- CONSULTING AGREEMENTS

The Company's total obligation to consultants as of June 30, 2007 was \$ 120. (For the complete information regarding the research and license agreement, see Note 4 to the financial statements as of December 31, 2006).

BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

In U.S. dollars in thousands (except share data)

NOTE 6:- SHORT-TERM CONVERTIBLE LOANS

a. On April 10, 2007, the Company issued a \$ 25 Convertible Promissory Note to a third party. Interest on the note will accrue at the rate of 8% per annum and will be due and payable in full on April 10, 2008. The note will become immediately due and payable upon the occurrence of certain Events of Default, as defined in the note. The third party has the right at any time prior to the close of business on the Maturity Date to convert all or part of the outstanding principal and interest amount of the note into shares of the Company's Common stock (the "Common stock"). The Conversion Price, as defined in the note, will be 75% (60% upon the occurrence of an Event of Default) of the average of the last bid and ask price of the Common stock as quoted on the Over-the-Counter Bulletin Board for the five trading days prior to the Company's receipt of the third party written notice of election to convert, but in no event the conversion price be greater than \$ 0.35 or more than 1,000,000 shares of Common stock be issued. The Conversion Price will be adjusted in the event of a stock dividend, subdivision, combination or stock split of the outstanding shares.

In addition, the Company granted to the shareholder warrants to purchase 25,000 of the Company's Common stock at an exercise price of \$ 0.45 per stock. The warrants are fully vested and are exercisable at any time after April 10, 2007, until the second anniversary of the issue date. The fair value of the warrants amounts to \$ 6.

In accordance with APB 14, the Company allocated the proceeds of convertible note issued with detachable warrants granted based on the relative fair values of the two securities at time of issuance. As a result, the Company recorded in its statement of changes in shareholders' equity an amount of \$ 4, in respect to the warrants and the convertible note was recorded in the amount of \$ 21.

The conversion feature, in the amount of \$ 8, embedded in the note was calculated based on a conversion rate of 75%. The amount was recorded as discount on the note against additional paid-in capital and is amortized to financial expenses over the note period.

The balance as of June 30, 2007, is comprised as follows:

Note	\$	21
Discount		(6)
Accrued interest		*) -
	\$	15

*) Represents an amount lower than \$ 1.

BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

In U.S. dollars in thousands (except share data)

NOTE 6:- SHORT-TERM CONVERTIBLE LOANS (Cont.)

b. On May 6, 2007, the Company issued a \$ 250 Convertible Promissory Note to a third party. Interest on the note will accrue at the rate of 8% per Annum and will be due and payable in full on May 6, 2008. The note will become immediately due and payable upon the occurrence of certain Events of Default, as defined in the note. The third party has the right at any time prior to the close of business on the Maturity Date to convert all or part of the outstanding principal and interest amount of the note into shares of the Company's Common stock (the "Common stock"). The Conversion Price, as defined in the note, will be 75% (60% upon the occurrence of an Event of Default) of the average of the last bid and ask price of the Common stock as quoted on the Over-the-Counter Bulletin Board for the five trading days prior to the Company's receipt of the third party written notice of election to convert but in no event the conversion price be greater than \$ 0.35 or more than 5,000,000 shares of Common stock be issued. The Conversion Price will be adjusted in the event of a stock dividend, subdivision, combination or stock split of the outstanding shares.

In addition, the Company granted to the third party warrants to purchase 250,000 shares of the Company's Common stock at an exercise price of \$ 0.45 per stock. The warrants are fully vested and are exercisable at any time after May 6, 2007 until May 31, 2010. The fair value of the warrants amounts to \$ 82.

In accordance with APB 14, the Company allocated the proceeds of convertible note issued with detachable warrants granted based on the relative fair values of the two securities at time of issuance. As a result the Company recorded in its statement of changes in shareholders' equity an amount of \$ 46, in respect to the warrants and the convertible note was recorded in the amount of \$ 204.

The conversion feature, in the amount of \$ 83, embedded in the note was calculated based on a conversion rate of 75%. The amount was recorded as discount on the note against additional paid-in capital and is amortized to financial expenses over the note period.

The balance as of June 30, 2007, is comprised as follows:

Note	\$	204
Discount		(71)
Accrued interest		3
	\$	136

BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

In U.S. dollars in thousands (except share data)

NOTE 7:-

STOCK CAPITAL

- a. The rights of Common stock are as follows:

Shares of Common stock confer upon their holders the right to receive notice to participate and vote in general meetings of the Company, the right to a share in the excess of assets upon liquidation of the Company and the right to receive dividends, if declared.

The Common stock of the company is registered and publicly traded on the Over-the-Counter Bulletin Board service of the National Association of Securities Dealers, Inc. under the symbol BCLI.

- b. The former president of the Company donated services valued at \$ 6 and rent valued at \$ 2 for the six months ended September 30, 2004. These amounts were charged to the statement of operations as part of discontinued operations and classified as additional paid in capital in the stockholders' equity.

- c. Issuance of stocks, warrants and options:

1. Private placements

- a) On June 24, 2004, the Company issued to investors 8,510,000 shares of Common stock for total proceeds of \$ 60 (net of \$ 25 issuance expenses).
- b) On February 23, 2005, the Company completed a private placement round for sale of 1,894,808 units for total proceeds of \$ 1,418. Each unit consists of one share of Common stock and a three year warrant to purchase one share of Common stock at \$ 2.50 per share. This private placement was consummated in four tranches which closed in October 2004, November 2004 and February 2005.
- c) On March 21, 2005, the Company entered into lock up agreements with 29 of its stockholders with respect to 15,290,000 shares held by them. Under these lock-up agreements, these stockholders may not transfer their shares to anyone other than permitted transferees without the prior consent of the Company' Board of Directors, for the period of time as follows: (i) 85% of the shares shall be restricted from transfer for the twenty-four month period following July 8, 2004, and (ii) 15% of the shares shall be restricted from transfer for the twelve month period following July 8, 2004.

On March 26, 2005, the Company completed amended lock up agreements with five of the twenty nine stockholders mentioned above with respect to 7,810,000 shares held by them. These lock-up Agreements amend and restate the previous lock-up agreements.

**BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)**

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

In U.S. dollars in thousands (except share data)

NOTE 7:- STOCK CAPITAL (Cont.)

Under the amended lock-up Agreements, these stockholders may not sell or otherwise transfer their stocks to anyone other than permitted transferees without the prior written consent of the Company's Board of Directors, as follows: (i) 85% of the shares will be restricted from transfer until December 31, 2006 and (ii) 15% of the shares will be free from the transfer restrictions. All of the restrictions under the amended lock-up Agreements will automatically terminate upon the effectiveness of any registration statement filed by the Company for the benefit of Ramot.

d) On May 12, 2005, the Company issued to a certain investor 186,875 shares of its Common stock for total proceeds of \$ 149 at a price per stock of \$ 0.8.

e) On July 27, 2005, the Company issued to certain investors 165,000 shares of its Common stock for total proceeds of \$ 99 at a price per stock of \$ 0.6.

f) On August 11, 2005, the Company signed a private placement agreement ("PPM") with investors for the sale of up to 1,250,000 units at a price per unit of \$ 0.8. Each unit consists of one share of Common stock and one warrant to purchase one share of Common stock at \$ 1.00 per share. The warrants are exercisable for a period of three years from issuance. On September 30, 2005, the Company sold 312,500 units for total net proceeds of \$ 225. On December 7, 2005, the Company sold 187,500 units for total net proceeds of \$ 135.

2. Share-based compensation to employees and to directors

a) Options to employees and directors:

On November 25, 2004, the Company's stockholders approved the 2004 Global Stock Option Plan and the Israeli Appendix thereto (which applies solely to participants who are residents of Israel) and on March 28, 2005, the Company's stockholders approved the 2005 U.S. Stock Option and Incentive Plan, and the reservation of 9,143,462 shares of Common stock for issuance in the aggregate under these stock option plans.

Each option granted under the plans is exercisable until the earlier of ten years from the date of grant of the option or the expiration dates of the respective option plans. The 2004 and 2005 options plans will expire on November 25, 2014 and March 28, 2015, respectively. The exercise price of the options granted under the plans may not be less than the nominal value of the shares into which such options are exercised. The options vest primarily over three or four years. Any options that are canceled or forfeited before expiration become available for future grants.

**BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)**

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

In U.S. dollars in thousands (except share data)

NOTE 7:- STOCK CAPITAL (Cont.)

As of June 30, 2007, 2,161,684 options are available for future grants.

On May 27, 2005, the Company granted one of its directors an option to purchase 100,000 shares of its Common stock, at an exercise price of \$ 0.75. The options are fully vested and are exercisable for a period of 10 years.

On February 6, 2006, the Company entered into an amendment to the Company's option agreement with Mr. David Stolick, the Company's Chief Financial Officer. The amendment changes the exercise price of the 400,000 options granted to him on March 29, 2005 to \$ 0.15 per share from \$ 0.75 per share.

On May 2, 2006, the Company granted to one of its directors an option to purchase 100,000 shares of its Common stock, at an exercise price of \$ 0.15. The options are fully vested and are exercisable for a period of 10 years.

On June 22, 2006, the Company entered into an amendment to the Company's option agreement with two of its employees. The amendment changes the exercise price of 270,000 options granted to them to \$ 0.15 per share from \$ 0.75 per share. The excess of the fair value resulting from the modification amounts to \$ 2 is recorded as general and administration expense over the remaining vesting period of the option.

On September 17, 2006, the Company entered into an amendment to the Company's option agreement with one of its directors. The amendment changes the exercise price of 100,000 options granted to them to \$ 0.15 per share from \$ 0.75 per share.

On March 21, 2007, the Company granted to one of its directors an option to purchase 100,000 shares of its Common stock, at an exercise price of \$ 0.15. The option is fully vested and is exercisable for a period of 10 years. The Compensation related to the options in the amount of \$ 43 was recorded as general and administrative expenses.

BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

In U.S. dollars in thousands (except share data)

NOTE 7:- STOCK CAPITAL (Cont.)

A summary of the Company's option activity related to options to employees and directors, and related information is as follows:

	Six months ended June 30, 2007	
	Amount of options	Weighted average exercise price \$
Outstanding at beginning of the period	2,850,760	\$ 0.188
Granted	890,000	0.434
forfeited	-	-
Outstanding at end of period	3,740,760	\$ 0.247
Vested and expected-to-vest options at end of period	2,534,381	\$ 0.178

Compensation expenses recorded by the Company in respect to its stock based employee compensation award in accordance with SFAS-123(R) for the six months ended June 30, 2007, amounted to \$ 530.

b) Restricted shares to directors:

On May 27, 2005, the Company issued to two of its directors 200,000 restricted shares of Common stock (100,000 each). The restricted shares are subject to the Company's right to repurchase them at a purchase price of par value (\$ 0.00005). The restrictions on the shares shall lapse in three annual and equal portions commencing with the grant date.

On May 2, 2006, the Company issued to two of its directors 200,000 restricted shares of Common stock (100,000 each). The restricted shares are subject to the Company's right to repurchase them at a purchase price of par value (\$ 0.00005). The restrictions of the shares shall lapse in three annual and equal portions commencing with the grant date. The compensation related to the stocks issued amounted to \$ 104, which will be amortized over the vesting period as general and administrative expenses.

**BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)**

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

In U.S. dollars in thousands (except share data)

NOTE 7:- STOCK CAPITAL (Cont.)

On April 20, 2007, based on board resolution dated March 21, 2007, the Company issued to its director 100,000 restricted shares of Common stock. The restricted shares are subject to the Company's right to repurchase them at a purchase price of par value (\$ 0.00005). The restrictions of the shares shall lapse in three annual and equal portions commencing with the grant date. The compensation related to the shares issued amounted to \$ 47, which will be amortized over the vesting period as general and administrative expenses.

In addition, on April 20, 2007, based on board resolution dated March 21, 2007, the Company issued to another director 100,000 restricted shares of Common stock. The restricted shares are not subject to any right to repurchase, and the compensation related to the shares issued amounted to \$ 47 was recorded as prepaid general and administrative expenses as of six months ended June 30, 2007.

3. Stocks and warrants to service providers and investors:

The Company accounts for stock option and warrant grants issued to non-employees using the guidance of SFAS No. 123(R), "Accounting for Stock-Based Compensation" and EITTF No. 96-18: "Accounting for Equity Instruments that are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services," whereby the fair value of such option and warrant grants is determined using the Black-Scholes options pricing model at the earlier of the date at which the non-employee's performance is completed or a performance commitment is reached.

BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

In U.S. dollars in thousands (except share data)

NOTE 7:-**STOCK CAPITAL (Cont.)**

Issuance date	Number of warrants	a)		Warrants exercisable	Warrants:
		Exercise price			Exercisable through
November 2004	12,800,845	\$	0.01	12,800,845	November 2010
December 2004	1,800,000	\$	0.00005	1,800,000	December 2014
	14,600,845			14,600,845	
February 2005, see c(1)	1,894,808	\$	2.5	1,894,808	February 2008
May 2005	47,500	\$	1.62	47,500	May 2010
June 2005	30,000	\$	0.75	30,000	June 2010
August 2005	70,000	\$	0.15	70,000	August 2008
September 2005	3,000	\$	0.15	3,000	September 2008
September 2005	36,000	\$	0.75	21,929	September 2010
September - December 2005	500,000	\$	1	500,000	September - December 2008
December 2005	20,000	\$	0.15	20,000	December 2008
December 2005	457,163	\$	0.15	235,053	July 2010
	17,659,316			17,423,135	
February 2006	230,000	\$	0.65	76,666	February 2008
February 2006	40,000	\$	1.5	40,000	February 2011
February 2006	8,000	\$	0.15	8,000	February 2011
February 2006	189,000	\$	0.5	189,000	February 2009
May 2006	50,000	\$	0.0005	50,000	May 2016
May -December 2006	48,000	\$	0.35	48,000	May - December 2011
May -December	48,000	\$	0.75	48,000	May - December

Edgar Filing: BRAINSTORM CELL THERAPEUTICS INC - Form 10QSB

2006			2011		
May 2006	200,000	\$ 1	200,000	May 2011	
June 2006	24,000	\$ 0.15	24,000	June 2011	
May 2006	19,355	\$ 0.15	19,355	May 2011	
October 2006	630,000	\$ 0.3	630,000	October 2009	
December 2006	200,000	\$ 0.45	200,000	December 2008	
19,345,671			18,956,156		
March 2007	200,000	\$ 0.47	200,000	March 2012	
March 2007	500,000	\$ 0.47	46,119	March 2017	
March 2007	50,000	\$ 0.15	50,000	March 2010	
March 2007	15,000	\$ 0.15	0	February 2012	
February 2007	50,000	\$ 0.45	50,000	February 2009	
March 2007	225,000	\$ 0.45	225,000	March 2009	
March 2007	50,000	\$ 0.45	50,000	March 2010	
April 2007	33,300	\$ 0.45	33,300	April 2009	
May 2007	250,000	\$ 0.45	250,000	May 2010	
20,718,971			19,860,575		

The fair value of warrants which became vested during the six months period ended June 30, 2007, amounted to \$ 296.

During the period from September 27, 2000 (inception) through June 30, 2007, no warrants, granted to service providers, were exercised or forfeited.

**BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)**

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

In U.S. dollars in thousands (except share data)

NOTE 7:- STOCK CAPITAL (Cont.)

The fair value for the warrants to service providers was estimated on the date of grant using Black-Scholes option pricing model, with the following weighted-average assumptions for the six months ended June 30, 2007, weighted average volatility of 115%, risk-free interest rates of 4.61% dividend yields of 0% and a weighted average life of the options of 7 years.

b) Stocks:

On June 1 and June 4, 2004, the Company issued 40,000 and 150,000 shares of Common stock, respectively for filing, legal and due-diligence services completed over a 12-month period with respect to a private placement. Compensation expenses related to filing services, totaling \$ 26, are amortized over a 12-month period. Compensation expenses related to legal services, totaling \$ 105 were recorded as equity issuance cost and did not affect the statement of operations.

On July 1 and September 22, 2004, the Company issued 20,000 and 15,000 shares of Common stock to a former director for financial services for the first and second quarters of 2004, respectively. Compensation expenses of \$ 39 were recorded as general and administrative expenses.

On February 10, 2005, the Company signed an agreement with one of its service providers according to which the Company issued the service provider 100,000 shares of restricted stock at a purchase price of \$ 0.00005 par value under the U.S Stock Option and Incentive Plan of the Company. The restricted shares are subject to the Company's right to repurchase them within one year of the grant date as follows: (i) in the event that service provider breaches his obligations under the agreement, the Company shall have the right to repurchase the restricted shares at a purchase price equal to par value; and (ii) in the event that the service provider has not breached his obligations under the agreement, the Company shall have the right to repurchase the restricted shares at a purchase price equal to the then fair market value of the restricted shares.

In March and April 2005, the Company signed an agreement with four members of its Scientific Advisory Board according to which the Company issued to the members of the Scientific Advisory Board 400,000 shares of restricted stock at a purchase price of \$ 0.00005 par value under the U.S. Stock Option and Incentive Plan (100,000 each). The restricted shares will be subject to the Company's right to repurchase them if the grantees cease to be members of the Company's Advisory Board for any reason. The restrictions on the shares shall lapse in three annual and equal portions commencing with the grant date.

In July 2005, the Company issued to its legal advisors 50,000 shares of Common stock for legal services for 12 months. The compensation related to the stocks in the amount of \$ 38 was recorded as general and administrative expenses.

**BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)**

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

In U.S. dollars in thousands (except share data)

NOTE 7:- STOCK CAPITAL (Cont.)

In January 2006, the Company issued to two service providers 350,000 restricted shares of Common stock at a purchase price of \$ 0.00005 par value under the U.S Stock Option and Incentive Plan of the Company. The restricted shares are subject to the Company's right to repurchase them within 12 months of the grant date as follows: (i) in the event that the service providers breach their obligations under the agreement, the Company shall have the right to repurchase the restricted shares at a purchase price equal to the par value; and (ii) in the event that the service providers have not breached their obligations under the service agreements the Company shall have the right to repurchase the restricted shares at a purchase price equal to the fair market value of the restricted shares. The compensation related to the restricted shares in the amount of \$ 23 was recorded as general and administrative expenses.

On March 6, 2006, the Company issued to its legal advisor 34,904 shares of the Company's Common stock. The shares are in lieu of \$ 19 payable to the legal advisor. Related compensation, in the amount of \$ 19 was recorded as general and administrative expenses.

On April 13, 2006, the Company issued to service providers 60,000 shares of the Company's Common stock at a purchase price of \$ 0.00005 par value under the U.S Stock Option and Incentive Plan of the Company. Related compensation in the amount of \$ 26 was recorded as general and administrative expenses.

On May 9, 2006, the Company issued to its legal advisor 65,374 shares of the Company's Common stock in lieu of legal services. Related compensation in the amount of \$ 33 was recorded as general and administrative expenses.

On June 7, 2006, the Company issued 50,000 shares of the Company's Common stock for filing services for 12 months. Related compensation in the amount of \$ 25 was recorded as general and administrative expenses.

On May 5, 2006, the Company issued 200,000 shares of the Company's Common stock to its finance consultant for his services. Related compensation in the amount of \$ 102 was recorded as general and administrative expenses.

On August 14, 2006, the Company issued 200,000 shares of the Company's Common stock to a service provider. Related compensation in the amount of \$ 68 was recorded as general and administrative expenses.

On August 17, 2006, the Company issued 100,000 shares of the Company's Common stock to a service provider. Related compensation in the amount of \$ 35 was recorded as general and administrative expenses.

**BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)**

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

In U.S. dollars in thousands (except share data)

NOTE 7:- STOCK CAPITAL (Cont.)

On September 17, 2006, the Company issued to its legal advisor 231,851 shares of the Company's Common stock. The stocks are in lieu of \$ 63 payable to the legal advisor.

During April 1 and September 30, 2006, the Company issued to its business development advisor, based on the agreement, 240,000 shares of the Company's Common stock. Related compensation in the amount of \$ 74 was recorded as general and administrative expenses.

On January 3, 2007, the Company issued to its legal advisor 176,327 shares of the Company's Common stock. The stocks are in lieu of \$ 45 payable to the legal advisor. Related compensation in the amount of \$ 49 was recorded as general and administrative expenses.

On April 12, 2007, the Company issued to its filing and printing service providers 80,000 shares. The shares issued in lieu of \$ 15 payable to the service provider. Compensation of \$ 30 was recorded as general and administrative expenses.

In addition, the Company is obligated to issue the filing and printing service providers additional shares, in the event that the total value of the shares hereby issued (as quoted on the Over-the-Counter Bulletin Board or such other exchange where the Common stock is quoted or listed) is less than \$20, on March 20, 2008. In no event shall the Company issue more than 30,000 additional shares to the service providers.

As a result, the Company recorded a liability in the amount of \$20.

On April 12, 2007, the Company issued to its legal advisor 108,511 shares of the Company's Common stock. The stocks are in lieu of \$ 29 payable to the legal advisor. Related compensation in the amount of \$ 40 was recorded as general and administrative expenses.

On May 18, 2007, the Company issued to its legal advisor 99,257 shares of the Company's Common stock. The stocks are in lieu of \$ 33, payable to the legal advisor. Related compensation in the amount of \$ 33 was recorded as general and administrative expenses

Pursuant to the terms of a \$50 Convertible Promissory Note, issued on February 5, 2007, to a certain shareholder, the Company received a written notice on May 28, 2007 from the shareholder to convert the entire accrued principal and interest amount of the convertible note into shares of the Company's Common stock. As a result, the Company issued 210,812 shares of the Company's Common stock to the shareholder.

BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

In U.S. dollars in thousands (except share data)

NOTE 7:- STOCK CAPITAL (Cont.)

Pursuant to the terms of a \$50 Convertible Promissory Note, issued on March 14, 2007, to a third party, the Company received a written notice on June 27, 2007 from the shareholder to convert the entire accrued principal and interest amount of the convertible note into shares of the Company's Common stock. As a result, the Company issued 225,346 shares of the Company's Common stock to the shareholder.

A summary of the Company's stocks award activity related to stocks issued to service providers, and related information is as follows:

	Six months ended June 30, 2007	
	Amount of shares	Weighted average issue price \$
Outstanding at beginning of the period	2,307,129	0.97
Issued	464,095	0.33
Outstanding at end of period	2,771,224	0.86

c. Stock-based compensation recorded by the Company in respect of stocks and warrants granted to service providers amounted to \$ 734 for the six months ended June 30, 2007.

NOTE 8:- SUBSEQUENT EVENTS

a. On July 3, 2007, the Company issued a \$ 30 Convertible Promissory Note to a shareholder. Interest on the Note will accrue at the rate of 8% per annum and will be due and payable in full on July 3, 2008. The Note will become immediately due and payable upon the occurrence of certain Events of Default, as defined in the Note. The third party has the right at any time prior to the close of business on the Maturity Date to convert all or part of the outstanding principal and interest amount of the Note into shares of the Company's Common stock (the "Common stock"). The Conversion Price, as defined in the Note, will be 75% (60% upon an event of default) of the average of the last bid and ask price of the Common stock as quoted on the Over-the-Counter Bulletin Board for the five trading days prior to the Company's receipt of the third party written notice of election to convert but in no event the conversion price be greater than \$ 0.35 or more than 1,000,000 shares of Common stock be issued. The Conversion Price will be adjusted in the event of a stock dividend, subdivision, combination or stock split of the outstanding shares.

In addition, the Company granted to shareholder warrants to purchase 30,000 shares of the Company's Common stock at an exercise price of \$ 0.45 per stock. The warrants are fully vested and are exercisable at any time after July 3, 2007, until the second anniversary of the issue date.

The Company agreed to pay finder's fee of \$ 3.

23

BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

In U.S. dollars in thousands (except share data)

NOTE 8:- SUBSEQUENT EVENTS (Cont.)

b. On July 3, 2007, the Company issued a \$ 100 Convertible Promissory Note to a third party. Interest on the Note will accrue at the rate of 8% per annum and will be due and payable in full on July 3, 2008. The Note will become immediately due and payable upon the occurrence of certain Events of Default, as defined in the Note. The third party has the right at any time prior to the close of business on the Maturity Date to convert all or part of the outstanding principal and interest amount of the Note into shares of the Company's Common stock (the "Common stock"). The Conversion Price, as defined in the Note, will be 75% of the average of the last bid and ask price of the Common stock as quoted on the Over-the-Counter Bulletin Board for the five trading days prior to the Company's receipt of the third party written notice of election to convert but in no event the conversion price be greater than \$ 0.35 or more than 2,000,000 shares of Common stock be issued. The Conversion Price will be adjusted in the event of a stock dividend, subdivision, combination or stock split of the outstanding shares.

In addition, the Company granted to the third party warrants to purchase 100,000 shares of the Company's Common stock at an exercise price of \$ 0.45 per stock. The warrants are fully vested and are exercisable at any time after July 3, 2007 until the third anniversary of the issue date.

The Company agreed to pay finder's fee of \$ 10.

c. On July 1, 2007, the Company's board of directors reached the following resolutions:

1. Issuance of 380,000 shares of Common stock of the Company to certain service providers.
2. Issuance of 1,250,000 shares to service provider as a finder fee for introduction to investor (see Note 8d).
3. Granting of options to purchase 750,000 shares of Common stock of the Company, to its consultants and employees at an exercise price of \$ 0.39. The options shall be vested in equal portions in 36 months from the day of grant and be exercisable for a period of 10 years.
4. Grant of options to purchase 100,000 shares of Common stock of the Company to one of its directors at an exercise price of \$ 0.15. The options shall be fully vested from the grant date and be exercisable for a period of 10 years.
5. Issuance of 200,000 restricted shares to two of the Company's directors.
6. Confirming the investment agreement with new investor for up to 5 millions dollar (see Note 8d).
7. Appointment of Chaim Lebovits as the president of the Company.

BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

In U.S. dollars in thousands (except share data)

NOTE 8:- SUBSEQUENT EVENTS (Cont.)

d. On July 2, 2007 the Company entered into an investment agreement, pursuant to which the Company agreed to sell up to 27,500,000 shares of the Company's Common stock, for an aggregate subscription price of up to \$5.0 million and warrants to purchase up to 30,250,000 shares of Common stock. Separate closings of the purchase and sale of the shares and the warrants shall take place as follows:

Purchase date	Purchase price	Number of subscription shares	Number of warrant shares
August 30, 2007	\$1,250,000 (includes \$250,000 that paid as a convertible loan (Note 6b))	6,875,000	7,562,500
November 15, 2007	\$750,000	4,125,000	4,537,500
February 15, 2008	\$750,000	4,125,000	4,537,500
May 15, 2008	\$750,000	4,125,000	4,537,500
July 30, 2008	\$750,000	4,125,000	4,537,500
November 15, 2008	\$750,000	4,125,000	4,537,500

At each closing date, the Company shall deliver to the investor the number of shares and warrants, subject to customary closing conditions and the delivery of funds, described above. The warrants shall have the following exercise prices: (i) the first 10,083,333 warrants will have an exercise price of \$ 0.20 per stock; (ii) the next 10,083,333 warrants will have an exercise price of \$ 0.29 per stock; and (iii) the final 10,083,334 Warrants issued will have an exercise price of \$ 0.36 per stock. Each warrant issued pursuant to the Subscription Agreement will expire on November 5, 2011.

Upon the first payment, on August 30 ,2007, the investor will surrender to the Company the form of promissory note and warrants issued to the Investor on May 6, 2007 (Note 6b), whereupon such promissory note and warrants will be deemed null and void.

In connection with the Agreement, the Company agreed to issue, upon the first closing date, as a finder's fee, 1,250,000 shares of Common stock of the Company to a third party.

On August 20, 2007, the investor paid \$1,000,000 as an advance for the first payment, and the Company issued to the investor an aggregate of 6,875,000 shares of common stock and a warrant to purchase 7,562,500 shares of the Company's common stock at an exercise price of \$0.20 per share. The warrant may be exercised at any time and expires on November 5, 2011.

BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

In U.S. dollars in thousands (except share data)

NOTE 8:- SUBSEQUENT EVENTS (Cont.)

e. On July 26, 2007 the Company entered into a Second Amended and Restated Research and License Agreement with Ramot. On August 1, 2007, the Company obtained a waiver and release from Ramot pursuant to which Ramot agreed to an amended payment schedule regarding the Company payment obligations under the amended license agreement, dated March 30, 2006, and waived all claims against the company resulting from the Company's previous defaults and non-payment under the original and first amended license agreement. The payments described in the waiver and release cover all of payment obligations that were past due and not yet due pursuant to the original license agreement. The waiver and release amends and restates the original payment schedule under the license agreement as follows:

Payment date	Amount
September 5, 2007	100,000
November 20, 2007	150,000
February 20, 2008	150,000
May 20, 2008	150,000
August 4, 2008	90,000

In addition, in the event that the "research period", as defined in the license agreement, is extended for an additional three year period in accordance with the terms of the license agreement, then the Company is obligated to the following payments to Ramot during the first year of the extended research period:

Payment date	Amount
August 4, 2008	60,000
November 20, 2008	150,000
February 20, 2009	170,000

If the Company fails to make a payment to Ramot on any required payment date, and the Company does not cure the default within seven business days of notice of the default, all claims of Ramot against the Company, which were waived and released, by the waiver and release, will be reinstated.

In addition, on August 1, 2007, the Company entered into the Second Amended and Restated Registration Rights Agreement with Ramot. According to the Second Amended and Restated Registration Rights Agreement, Ramot waived their demand for registration rights, according to the amended registration rights agreement dated March 31, 2006, and instead agreed to piggyback registration rights in the event that the Company files a registration statement (subject to customary exceptions).

Item 2. Plan of Operation.

Company Overview

Brainstorm Cell Therapeutics Inc. (“Brainstorm” or the “Company”) is an emerging company developing stem cell therapeutic products based on breakthrough technologies enabling the in vitro differentiation of bone marrow stem cells to neural-like cells. We aim to become a leader in adult stem cell transplantation for neurodegenerative diseases. Our focus is on utilizing the patient’s own bone marrow stem cells to generate neuron-like cells that may provide an effective treatment initially for Parkinson’s disease (PD) and ALS, and thereafter for Multiple Sclerosis and other neurodegenerative disorders.

Recent Developments

New President and Board Member

On July 2, 2007, Chaim Lebovits was appointed the President of the Company.

On July 16, 2007, the Board of Directors of the Company increased the size of the Board to four members and elected Mr. Moshe Lion to the Board.

New Advisory Board

In August 2007, we established an Advisory Board comprised of world class business leaders. The Advisory Board is still in development, and we are working to add additional qualified members.

Research Developments

On February 8, 2007 in laboratories at the University of Navarra, Pamplona, Spain, Prof. Jose Obeso transplanted the subject, a healthy monkey, with our human bone marrow derived mesenchymal stem cells. The stem cells had been induced to differentiate into neurotrophic factor-producing cells, according to the protocol developed at our laboratories in Israel. The monkey was treated daily with cyclosporine to prevent rejection of the human originating cells by its immune system, and was monitored for a variety of parameters for a period of three months. Throughout this phase, the monkey appeared well and in good health, with a usual appetite, and with no apparent change in physical and behavioral parameters. Blood tests, an MRI of the monkey's brain and an autopsy examination of the internal organs were also found to be normal.

Additionally, brain tissues from the monkey were examined by Prof. Jeffrey Kordower (Rush University, Chicago, USA). A few human originating cells were detected in sections of the monkey's brain by staining the sections with an antibody, which can distinguish between the monkey's own brain cells and the human transplanted cells. The human transplanted cells were surrounded by macrophages, which may indicate a reaction of the monkey's immune system to the transplanted human cells and their initial rejection. Our approach would involve autologous transplantation (i.e., the use of the patient's own bone marrow-derived stem cells). With this strategy, no rejection is expected and there will be no need to suppress the immune system by medications that often cause severe side effects.

Two additional normal monkeys recently underwent transplantation in Pamplona with our human stem cells. The monkeys will also be monitored for a period of three months for collection of additional data; so far, the monkeys are in good health.

Double U Master Fund

In July 2007, we entered into a letter agreement with Double U Master Fund L.P. pursuant to which we agreed to issue to Double U an aggregate of 630,000 shares of common stock upon exercise of a common stock purchase warrant dated as of October 3, 2006 held by Double U. In lieu of paying the purchase price for the shares in cash, Double U agreed to waive the repayment of the promissory note we issued to Double U on February 1, 2006 in the principal amount of \$189,000, except for accrued interest of \$17,340. Upon payment of the accrued interest and issuance of the 630,000 shares to Double U, all of our obligations owed to Double U under the February 1, 2006 note and the common stock purchase warrant were satisfied in full.

Second Amended License Agreement with Ramot at Tel Aviv University Ltd.

We entered into a Second Amended and Restated Research and License Agreement with Ramot at Tel Aviv University Ltd. on July 26, 2007. Like the original license agreement with Ramot, the amended license agreement imposes on us development and commercialization obligations, milestone and royalty payment obligations and other obligations. As of June 30, 2007, we owed Ramot an aggregate of \$513,249 in overdue payments and patent fees under the original license agreement with Ramot. On August 1, 2007, we obtained a waiver and release from Ramot pursuant to which Ramot agreed to an amended payment schedule regarding our payment obligations under the amended license agreement and waived all claims against us resulting from our previous breaches, defaults and non-payment under the original license agreement. The payments described in the waiver and release cover all of our payment obligations (including interest) that were past due and not yet due pursuant to the original license agreement. The waiver and release amends and restates the original payment schedule under the license agreement as follows:

Payment Date	Amount
September 5, 2007	\$ 100,000
November 20, 2007	\$ 150,000
February 20, 2008	\$ 150,000
May 20, 2008	\$ 150,000
August 4, 2008	\$ 90,000

In addition, in the event that the “research period”, as defined in the license agreement, is extended for an additional three year period in accordance with the terms of the license agreement, then we must make the following payments to Ramot during the first year of the extended research period:

Payment Date	Amount
August 4, 2008	\$ 60,000
November 20, 2008	\$ 150,000
February 20, 2009	\$ 170,000

If we fail to make a payment to Ramot on any required payment date, and we do not cure the default within seven business days of notice of the default, all claims of Ramot against us which were waived and released by the waiver and release will be reinstated.

In addition, on August 1, 2007, we entered into the Second Amended and Restated Registration Rights Agreement with Ramot. The amended Registration Rights Agreement provides Ramot with demand and piggyback registration rights whereby if we propose to register any of our common stock under the Securities Act of 1933, as amended, for sale for our own account including for the account of any of our shareholders or for ACCBT Corp.’s account in connection with the public offering of such common stock, then Ramot may request that the we file, or include within a registration statement to be filed, the shares of common stock underlying the warrants held by Ramot.

Investment Agreement with ACCBT Corp.

On July 2, 2007, we entered into a subscription agreement with ACCBT Corp., a company under the control of Mr. Chaim Lebovits, our newly appointed President, pursuant to which we agreed to sell (i) up to 27,500,000 shares of our common stock for an aggregate subscription price of up to \$5.0 million, and (ii) for no additional consideration, warrants to purchase up to 30,250,000 shares of our common stock. Subject to certain closing conditions, separate closings of the purchase and sale of the shares and the warrants are scheduled to take place from August 30, 2007 through November 15, 2008. The warrants will have the following exercise prices: (i) the first 10,083,333 warrants will have an exercise price of \$0.20; (ii) the next 10,083,333 warrants will have an exercise price of \$0.29; and (iii)

the final 10,083,334 warrants will have an exercise price of \$0.36. Because of our recent resolution and restructuring of the amounts owed by us to Ramot under the Ramot license agreement, ACCBT elected to accelerate the date of the first closing under the subscription agreement from August 30, 2007 to August 10, 2007. Therefore, on August 20, 2007, we received an aggregate of \$1,000,000 from ACCBT, and we will issue to ACCBT an aggregate of 6,875,000 shares of common stock and a warrant to purchase an aggregate of 7,562,500 shares of common stock.

As a condition to each closing under the subscription agreement, the market price per share of our common stock may not be 10% less than the bid price per share under the subscription agreement on any trading day between 30 and 10 days prior to any given closing date. If at any time prior to the first closing date we issue shares of common stock or other securities convertible into, exercisable or exchangeable for common stock, then the number of shares to be issued to ACCBT under the subscription agreement and the price per share will be adjusted so that ACCBT will have the right to purchase up to 52.35% of our equity on a fully diluted as converted basis (assuming ACCBT purchases all of the shares and exercises in full all of the warrants subject to the subscription agreement) and 50.02% of the issued and outstanding shares of our common stock (assuming ACCBT invests the full \$5.0 million).

Pursuant to the subscription agreement, ACCBT and certain other security holders of the Company holding at least 31% of the issued and outstanding shares of our common stock entered into a Security Holders Agreement. The security holders party to the Security Holders Agreement agreed, upon the payment by ACCBT of its first \$1.0 million under the subscription agreement, to vote all of their shares such that ACCBT's nominees to our Board of Directors will constitute a minimum of 40% of the Board of Directors, and, upon the payment by ACCBT of its second \$1.0 million, to vote all of their shares such that ACCBT's nominees will constitute a minimum of 50.1% of the Board of Directors. However, if ACCBT stops making payments after the first closing date such that ACCBT pays us less than \$4.0 million, ACCBT will be entitled to appoint only 40% of the members of our Board of Directors.

The security holders party to the Security Holders Agreement also agreed, for so long as ACCBT holds at least 5% of the issued and outstanding shares of our common stock, not to vote any of their shares to approve the following matters, without the written consent of ACCBT: (i) any change in our certificate of incorporation or bylaws, or alteration of our capital structure; (ii) the declaration or payment of a dividend or the making of any distributions; (iii) the taking of any steps to liquidate, dissolve, wind-up or otherwise terminate our corporate existence; or (iv) the entering into any transaction the effect of which would place control of our business in the hands of an arm's length third party.

In connection with the subscription agreement, we agreed to issue, upon the first closing date, as a finder's fee, 1,250,000 shares of our common stock to Tayside Trading Ltd. or its registered assigns.

Transfer of Warrant from Ramot at Tel Aviv University Ltd. to ACCBT Corp.

Pursuant to the terms of a Warrant Purchase Agreement, dated August 2, 2007, between Ramot at Tel Aviv University Ltd. and ACCBT Corp., Ramot has agreed to transfer and sell to ACCBT (or to certain parties that may be designated by ACCBT), a warrant to purchase an aggregate of 3,181,925 shares of our common stock for an aggregate purchase price of \$636,385. The warrant is exercisable at any time for an exercise price per share equal to \$0.01. The warrant will expire on November 4, 2010. The closing of the transfer and sale of the warrant from Ramot to ACCBT is expected to take place on August 31, 2007.

Accrued Interest Owed to Zegal & Ross Capital

We owe an aggregate of \$80,000 to Zegal & Ross Capital and Mark Zegal under various outstanding promissory notes issued by us to Zegal & Ross Capital and Mark Zegal. In August 2007, Zegal & Ross Capital and Mr. Zegal each agreed to waive the payment by us of all accrued interest under the outstanding promissory notes, which accrued interest was \$5,800 as of August 1, 2007.

Adult Stem Cell Therapy

Our activities are within the stem cell therapy field. Stem cells are non-specialized cells with a potential for both self-renewal and differentiation into cell types with a specialized function, such as muscle, blood or brain cells. The cells have the ability to undergo asymmetric division such that one of the two daughter cells retains the properties of the stem cell, while the other begins to differentiate into a more specialized cell type. Stem cells are therefore central to normal human growth and development, and also are a potential source of new cells for the regeneration of diseased and damaged tissue. Stem cell therapy aims to restore diseased tissue function by the replacement and/or addition of healthy cells by stem cell transplants.

Currently, two principal platforms for cell therapy products are being explored: (i) embryonic stem cells ("ESC"), isolated from the inner mass of a few days old embryo; and (ii) adult stem cells, sourced from bone marrow, cord blood and various organs. Although ESCs are the easiest to grow and differentiate, their use in human therapy is limited by safety concerns associated with their tendency to develop Teratomas (a form of tumor) and their potential

to elicit an immune reaction. In addition, ESC has generated much political and ethical debate due to their origin in early human embryos.

Cell therapy using adult stem cells does not suffer from the same concerns. Bone marrow is the tissue where differentiation of stem cells into blood cells (haematopoiesis) occurs. In addition, it harbors stem cells capable of differentiation into mesenchymal (muscle, bone, fat and other) tissues. Such mesenchymal stem cells have also been shown capable of differentiating into nerve, skin and other cells. In fact, bone marrow transplants have been safely and successfully performed for many years, primarily for treating leukemia, immune deficiency diseases, severe blood cell diseases, lymphoma and multiple myeloma. Moreover, bone marrow may be obtained through a simple procedure of aspiration, from the patient himself, enabling autologous cell therapy, thus obviating the need for donor matching, circumventing immune rejection and other immunological mismatch risks, as well as avoiding the need for immunosuppressive therapy. Thus, we believe bone marrow, in particular autologous bone marrow, capable of in vitro growth and multipotential differentiation, presents a preferable source of therapeutic stem cells.

Parkinson's Disease ("PD")

Background

PD is a chronic, progressive disorder, affecting certain nerve cells, which reside in the Substantia Nigra of the brain and which produce dopamine, a neurotransmitter that directs and controls movement. In PD, these dopamine-producing nerve cells break down, causing dopamine levels to drop below the threshold levels and resulting in brain signals directing movement to become abnormal. The cause of the disease is unknown.

Over four million people suffer from PD in the western world, of whom about 1.5 million are in the United States. In over 85% of cases, PD occurs in people over the age of 65. Thus, prevalence is increasing in line with the general aging of the population. We believe the markets for pharmaceutical treatments for PD have a combined value of approximately \$4 billion per year. However, these costs are dwarfed when compared to the total economic burden of the disease, which has been estimated by the National Institute of Neurological Disease (NINDS) to exceed \$26 billion annually in the U.S. alone, including costs of medical treatment, caring, facilities and other services, as well as loss of productivity of both patients and caregivers.

Description

The classic symptoms of PD are shaking (tremor), stiff muscles (rigidity) and slow movement (bradykinesia). A person with fully developed PD may also have a stooped posture, a blank stare or fixed facial expression, speech problems and difficulties with balance or walking. Although highly debilitating, the disease is not life threatening and an average patient's life span is approximately 15 years.

Current Treatments

Current drug therapy for PD primarily comprises dopamine replacement, either directly (levodopa), with dopamine mimetics or by inhibition of its breakdown. Thus, the current drugs focus on treating the symptoms of the disease and do not presume to provide a cure.

Levodopa, which remains the standard and most potent PD medication available, has a propensity to cause serious motor response complications (MRCs) with long-term use. Moreover, effective drug dosage often requires gradual increase, leading to more adverse side effects and eventual resistance to their therapeutic action. This greatly limits patient benefit. Therefore, physicians and researchers are continuously seeking levodopa-sparing strategies in patients with early-stage disease to delay the need for levodopa, as well as in patients with late stage disease who no longer respond to therapy.

Prescription drugs to treat PD currently generate sales of over \$1 billion and the market is expected to grow to approximately \$2.3 billion by 2010, driven by the increase in size of the elderly population and the introduction of new PD therapies that carry a higher price tag than the generic levodopa.

Another method for treating PD is Deep Brain Stimulation (DBS), which consists of transplanting electrodes deep into the brain to provide permanent electrical stimulation to specific areas of the brain and to cause a delay in the activity in those areas. However, DBS is problematic as it often causes uncontrollable and severe side effects such as bleeding in the brain, infection and depression. In addition, like drug therapy, DBS focuses on treating the symptoms of PD and does not provide a cure.

There is a greatly unsatisfied need for novel approaches towards management of PD. These include development of neurotrophic agents for neuroprotection and/or neurorestoration, controlling levodopa-induced adverse side effects, developing compounds targeting nondopaminergic systems (e.g., glutamate antagonists) controlling the motor dysfunction such as gait, freezing, and postural imbalance, treating and delaying the onset of disease-related dementia and providing simplified dosing regimens.

In addition to the symptomatic drug development approaches, there is an intense effort to develop cell and gene therapeutic "curative" approaches to restore the neural function in patients with PD, by (i) replacing the dysfunctional cells with dopamine producing cell transplant, or by (ii) providing growth factors and proteins, such as glial derived neurotrophic factor (GDNF), that can maintain or preserve the patient's remaining dopaminergic cells, protecting them from further degeneration. Preclinical evaluation of cell therapeutic approaches based on transplantation of dopaminergic neurons differentiated in vitro from ESC, have been successful in ameliorating the parkinsonian behavior of animal models, as has direct gene therapy with vectors harboring the GDNF gene. However, these approaches are limited, in the first case, by the safety and ethical considerations associated with use of ESC, and, in the second case, by the safety risks inherent to gene therapy.

In fact, PD is the first neurodegenerative disease for which cell transplantation has been attempted in humans, first with adrenal medullary cells and, later, with tissue grafts from fetal brain. About 300 such fetal transplants have already been performed and some benefits have been observed, mainly in younger patients. However, this approach is not only impractical but greatly limited by the ethical issues influencing the availability of human fetuses. The above

considerations have led to intensive efforts to define and develop appropriate cells from adult stem cells.

Amyotrophic Lateral Sclerosis ("ALS")

ALS, often referred to as "Lou Gehrig's disease," is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. Motor neurons reach from the brain to the spinal cord and from the spinal cord to the muscles throughout the body. The progressive degeneration of the motor neurons in ALS eventually leads to death. As motor neurons degenerate, they can no longer send impulses to the muscle fibers that normally result in muscle movement. With voluntary muscle action progressively affected, patients in the later stages of the disease may become completely paralyzed. However, in most cases, mental faculties are not affected.

Approximately 5,600 people in the U.S. are diagnosed with ALS each year. It is estimated that as many as 30,000 Americans may have the disease at any given time, with 100,000 across the western world. Consequently, the total estimated cost of treating ALS patients in the United States is approximately \$1.25 billion per year and \$3 billion per year in the western world.

Description

Early symptoms of ALS often include increasing muscle weakness or stiffness, especially involving the arms and legs, speech, swallowing or breathing.

ALS is most often found in the 40 to 70 year age group, where it is actually quite common, with the same incidence as Multiple Sclerosis (MS). There appear to be more MS sufferers because MS patients tend to live much longer, some for 30 years or more. The life expectancy of an ALS patient averages about two to five years from the time of diagnosis. However, up to 10% of ALS patients will survive more than ten years.

Current Treatment

The physician bases medication decisions on the patient's symptoms and the stage of the disease. Some medications used for ALS patients include:

- o Riluzole - the only medication approved by the FDA to slow the progress of ALS. While it does not reverse ALS, riluzole has been shown to reduce nerve damage. Riluzole may extend the time before a patient needs a ventilator (a machine to help breathe) and may prolong the patient's life by several months;
- o Baclofen or Diazepam - these medications may be used to control muscle spasms, stiffness or tightening (spasticity) that interfere with daily activities; and
- o Trihexyphenidyl or Amitriptyline - these medications may help patients who have excess saliva or secretions, and emotional changes.

Other medications may be prescribed to help reduce such symptoms as fatigue, pain, sleep disturbances, constipation, and excess saliva and phlegm.

Our Approach

We intend to focus our efforts to develop cell therapeutic treatments for PD based on the expansion of human mesenchymal stem cells from adult bone marrow and their differentiation into neuron like cells, such as neurons that produce dopamine and astrocytes (glial cells) that produce neurotrophic factors (NTF) including GDNF, BDNF, NGF and IGF-1. Our aim is to provide neural stem cell transplants that (i) "replace" damaged dopaminergic nerve cells and diseased tissue by augmentation with healthy dopamine producing cells; and (ii) maintain, preserve and restore the damaged and remaining dopaminergic cells in the patient's brain, protecting them from further degeneration.

The research team led by Prof. Melamed and Dr. Offen has achieved expansion of human bone marrow mesenchymal stem cells and their differentiation into both types of brain cells, neurons and astrocytes, each having therapeutic potential, as follows:

NurOwn™ program 1 - DA neuron-like cells - human bone marrow derived dopamine producing neural cells for restorative treatment in PD. Human bone marrow mesenchymal stem cells were isolated and expanded. Subsequent differentiation of the cell cultures in a proprietary differentiation medium generated cells with neuronal-like morphology and showing protein markers specific to neuronal cells. Moreover, the in vitro differentiated cells were shown to express enzymes and proteins required for dopamine metabolism, particularly the enzyme tyrosine hydroxylase. Most importantly, the cells produce and release dopamine in vitro. Further research consisting of implanting these cells in an animal model of PD (6-OHDA induced lesions), showed the differentiated cells exhibit long-term engraftment, survival and function in vivo. Most importantly, such implantation resulted in marked attenuation of their symptoms, essentially reversing their Parkinsonian movements.

NurOwn™ program 2 - Astrocyte-like cells - human bone marrow derived NTF producing astrocyte for treatment of PD, ALS and spinal cord injury. In vitro differentiation of the expanded human bone marrow derived mesenchymal stem cells in a special proprietary medium and generated cells with astrocyte-like morphology that expressed astrocyte specific markers. Moreover, the in vitro differentiated cells were shown to express and secrete GDNF, as other NTF, into the growth medium. GDNF is a protein, previously shown to protect, preserve and even restore neurons, particularly dopaminergic cells in PD, but also neuron function in other neurodegenerative pathologies such as ALS and Huntington's. Unfortunately, therapeutic application of GDNF is hampered by its poor brain penetration and stability. Attempting to infuse the protein directly to the brain is impractical and the alternative, using GDNF gene therapy, suffers from the limitations and risks of using viral vectors. Our preliminary results show that our astrocyte-like cells, when transplanted into PD rats with a 6-OHDA lesion, show significant efficacy. Within weeks of the transplantation, there was an improvement of more than 50% in the animals' characteristic disease symptoms.

We intend to optimize the proprietary processes for transformation of human bone marrow expanded mesenchymal stem cells into differentiated cells that produce dopamine and/or NTF for implantation to PD and ALS patients. The optimization and process development will be conducted in an effort to comply with FDA guidelines for Good Tissue Practice (GTP) and Good Manufacturing Practice (GMP). Once the optimization of the process is completed, we intend to evaluate the safety and efficacy of our various cell transplants in animal models, (separately and in combination). Based on the results in animals we intend to use the differentiated cell products for conducting clinical trials to assess the efficacy of the cell therapies in PD and ALS patients.

Our technology is based on the NurOwn™ products - an autologous cell therapeutic modality, comprising the extraction of the patient bone marrow, processed into the appropriate neuronal cells and re-implanted into the patient's brain. This approach is taken in order to increase patient safety and minimize any chance of immune reaction or cell rejection.

We believe that the therapeutic modality will comprise the following:

- o Bone marrow aspiration from patient;
- o Isolating and expanding the mesenchymal stem cells;
- o Differentiating the expanded stem cells into neuronal-like dopamine producing cells and/or astrocytes-like NTF producing cells; and
- o Implantation of the differentiated cells into patient from whom the bone marrow was extracted.

Business Strategy

Our efforts are currently focused on the development of the technology to convert the process from the lab stage to the clinical stage, with the following main objectives:

- o Developing the cell differentiation process according to health regulation guidelines;
- o Demonstrating safety and efficacy, first in animals and then in patients; and
- o Setting up centralized facilities to provide NurOwn™ therapeutic products and services for transplantation in patients.

We intend to enter into strategic partnerships as we progress towards advanced clinical development and commercialization with companies responsible for advanced clinical development and commercialization. This approach is intended to generate an early inflow of up-front and milestone payments and to enhance our capacities in regulatory and clinical infrastructure while minimizing expenditure and risk.

Intellectual Property

We have filed the following patent and trademark applications:

- o The NurOwn™ technology for differentiation of dopamine producing neuron-like cells is covered by PCT patent application number PCT/IL03/00972 filed on November 17, 2003.
- o The NurOwn™ technology for differentiating astrocyte-like cells is covered by PCT patent application number PCT/IL2006/000699 filed on June 18, 2006.
- o The NurOwn™ technology for generating oligodendrocyte-like cells treatment of medical conditions of the CNS is covered by PCT patent application number PCT/IL2006/001410 filed on December 7, 2006.
- o We have filed for a trademark on NurOwn™.

Assuming we can successfully complete our additional necessary financings, our primary objectives over the next twelve (12) months will be:

- To define and optimize our NurOwn™ technology in human bone marrow cells, in order to prepare the final production process for clinical studies in accordance with health authorities' guidelines. To reach this goal we intend to optimize methods for the stem cell growth and differentiation in specialized growth media, as well as methods for freezing, thawing, storing and transporting of the expanded mesenchymal stem cells, as well as the differentiated neuronal cells;

- To verify the robustness and the reproducibility of the process;
- To further repeat the process using bone marrow from Parkinson's patients;
- To conduct large efficacy studies in animal models of PD (such as mice and rats) in order to further evaluate the engraftment, survival and efficacy of our astrocyte-like cell in these models;
- To finish conducting safety and efficacy studies in primates-monkeys;
- To conduct a full tumorigenicity study in animals;
- To generate process SOPs, protocols and reports for the file submission;
- To finalize analytical methodology and product specifications to be used as release criteria of the final cell product for clinical trials in humans;
- To set up a quality control system for the processing of our cells; and
- To write up clinical protocols for phase I & II clinical studies, and start the clinical trials.

All of these activities will be coordinated with a view towards the execution of clinical trials of the astrocyte-like differentiated cell implants in humans. We intend to crystallize our development plans with the assistance of our scientific advisory board members and external regulatory consultants who are experts in the FDA cell therapy regulation guidelines.

In addition, we intend to identify and evaluate in-licensing opportunities for development of innovative technologies utilizing cell and gene therapy for diabetes, cardiac disease and other indications.

Cash Requirements

At June 30, 2007, we had \$123,000 in total current assets and \$3,648,000 in total current liabilities and on August 9, 2007, we had approximately \$93,000 in cash. On August 20, 2007, the Company received \$1,000,000 from ACCBT Corp. If ACCBT Corp. chooses to continue funding the Company as set forth in the Subscription Agreement, then we expect that we will receive five installments of \$750,000 every quarter through November 2008. We will need to raise additional funds through public or private debt or equity financings to meet our anticipated expenses for the coming years so that we can execute our business plan and conduct clinical trials in PD and ALS patients. Although we have been seeking such additional funds, no commitments to provide additional funds have been made by management, other shareholders or third parties.

In order to execute our plan of operation for the next several years we will need to raise additional financing.

In the past, we have received loans from various investors. In connection with such loans, we have issued convertible notes. As of August 14, 2007, we owed certain investors approximately \$1.1 million in overdue payments under certain convertible notes. We are currently in discussions with such investors to obtain a deferral of these payments until we raise additional capital.

Our other material cash needs for the next 12 months will include employee salaries and benefits, facility lease, capital equipment expenses and construction of facilities for animals we plan to use in our research and development and trials, legal and audit fees, patent prosecution fees, consulting fees, payments for outsourcing of certain animal

experiments and, possibly, upfront payments for in-licensing opportunities and payment for clinical trials in Europe or the U.S.

Research and Development

Our research and development efforts have focused on improving growth conditions and developing tools to evaluate the differentiation of bone marrow stem cells into neural-like cells, suitable for transplantation as a restorative therapy for neurodegenerative diseases. Some highlights achieved in this research include:

33

- Improving the bone marrow stem cells expansion prior to differentiation;
- Evaluation of methodologies for cryo-preservation of the expanded bone marrow cells prior to differentiation;
- Characterization of the propagated mesenchymal stem according to established CD-markers;
- Determination of timing and growth conditions for the differentiation process;
- Development of molecular tools and cell surface markers to evaluate cell differentiation;
- Demonstrating that the bone marrow derived differentiated cells do produce and secrete several neuron-specific markers;
- Transplantation of the bone marrow derived neural-like cells in the striatum of model animals resulting in long-term engraftment; and
- Parkinson's model animals transplanted with the bone marrow derived neural-like cells show significant improvement in their rotational behavior.

For the twelve months ending June 30, 2008, we estimate that our research and development costs will be approximately \$4 million excluding compensation expenses related to options and warrants. We intend to spend our research and development costs on the development of our core NurOwn™ technology by developing the cell differentiation process according to FDA and/or EMEA guidelines and to finish the primate clinical trials in Spain. We also plan to construct a facility for animals we plan to use in our research and development and trials. We also intend to fund and finance collaborations with medical centers and strategic partners for future clinical trials.

General and Administrative Expenses

If we can successfully complete our financings, for the twelve months ending June 30, 2008, we estimate that our general and administrative expenses will be approximately \$1 million excluding compensation expenses related to options, warrants and shares. These general and administrative expenses will include, among others, salaries, legal and audit expenses, business development, investor and public relations, Sarbanes-Oxley compliance expenses and office maintenance.

We do not expect to generate any revenues in the twelve-month period ending June 30, 2008.

In management's opinion, we need to achieve the following events or milestones in the next twelve months in order for us to conduct clinical trials for our NurOwn™ dopamine or astrocyte-like producing cell differentiation process as planned within the next several years:

- Complete preclinical studies in rodents to confirm safety and efficacy;
- Complete preclinical studies to confirm safety in monkeys;
- Conduct full safety study of the final cell product for PD;
- Write up clinical protocols for Phase I & II clinical studies; and

Raise additional equity or debt financing or a combination of equity and debt financing in addition to the \$5,000,000 from ACCBT Corp. that we expect to receive under the recent subscription agreement.

Employees

We currently have eleven scientific and administrative employees. We expect to increase our staff significantly in the coming months in order to reach our goals.

34

Off Balance Sheet Arrangements

We have no off balance sheet arrangements that have or are reasonably likely to have a current or future material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources.

Risk Factors

Any investment in our common stock involves a high degree of risk. You should consider carefully the risks described below, together with the other information contained in this report. If any of the following events actually occurs, our business, financial condition and results of operations may suffer materially. As a result, the market price of our common stock could decline, and you could lose all or part of your investment in our common stock.

In addition to the other information set forth in this report, you should carefully consider the factors discussed in “Risk Factors” in our report on Form 10-KSB for the transition period ended December 31, 2006, which could materially affect our business, financial condition or future results. The risks described in our transition report on Form 10-KSB are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results. The risk factors below were disclosed in our annual report on Form 10-KSB and have been updated to provide information as of June 30, 2007.

Our business in the foreseeable future will be based on technology licensed from Ramot and if this license were to be terminated for any reason, including failure to pay the required research funding or royalties, we would need to change our business strategy and we may be forced to cease our operations. We entered into a Second Amended and Restated Research and License Agreement with Ramot on July 31, 2007 (the “Amended Agreement”). The Amended Agreement imposes on us development and commercialization obligations, milestone and royalty payment obligations and other obligations.

As of June 30, 2007, we owed Ramot an aggregate of \$513,000 in overdue payments and patent fees under our original license agreement with Ramot. On August 1, 2007, we obtained a waiver and release from Ramot pursuant to which Ramot agreed to an amended payment schedule regarding our payment obligations under the Amended Agreement and waived all claims against us resulting from our previous breaches and non-payment under the original license agreement. The payments described in the waiver and release cover all of our payment obligations (including interest) that were past due and not yet due pursuant to the original license agreement. The waiver and release provides that we are obligated to pay Ramot fees ranging from \$90,000 to \$150,000 on a quarterly basis from September 2007 until August 2008, and, if certain research milestones are met, we are obligated to make payments to Ramot ranging from \$60,000 to \$170,000 on a quarterly basis from August 2008 until February 2009. If we fail to pay the amounts owed to Ramot in accordance with the new payment schedule, Ramot may have the right to terminate the license and all claims waived by Ramot pursuant to the waiver and release may be reinstated. If Ramot elects to terminate our license, we would need to change our business strategy and we may be forced to cease our operations.

In addition, on August 1, 2007, we entered into a Second Amended and Restated Registration Rights Agreement with Ramot relating to warrants to purchase shares of our common stock at a purchase price of \$0.01 per share issued to Ramot in connection with the original Ramot agreement. The Registration Rights Agreement extends the date by which the shares underlying the warrants are to be registered by us for resale to no later than within 30 days after the earlier of (i) the Company registering shares of its common stock for issuance by the Company, or (ii) the date on which shares of common stock held by ACCBT Corp. are registered for resale.

Our company has a history of losses and we expect to incur losses for the foreseeable future. We had no revenues for the fiscal years ended March 31, 2005 or March 31, 2006 or for the transition period from April 1, 2006 to

December 31, 2006 or for the six months ended June 30, 2007. As a development stage company, we are in the early stages of executing against our business plan. Our ability to operate successfully is materially uncertain and our operations are subject to significant risks inherent in a developing business enterprise. Most notably, we do not expect that any therapies resulting from our or our collaborators' research and development efforts will be commercially available for a significant number of years, if at all. We also do not expect to generate revenues from strategic partnerships or otherwise for at least the next 12 months, and likely longer. Furthermore, we expect to incur substantial and increasing operating losses for the next several years as we increase our spending to execute our development programs. These losses are expected to have an adverse impact on our working capital, total assets and stockholders' equity, and we may never achieve profitability.

However, in the last month, we have made significant progress and improvements to our financial condition. For example, on July 2, 2007, we entered into a subscription agreement with ACCBT Corp., a company under the control of Mr. Chaim Lebovits, our newly appointed President, pursuant to which we agreed to sell (i) up to 27,500,000 shares of our common stock for an aggregate subscription price of up to \$5.0 million, and (ii) for no additional consideration, warrants to purchase up to 30,250,000 shares of our common stock. Subject to certain closing conditions, separate closings of the purchase and sale of the shares and the warrants are scheduled to take place from August 30, 2007 through November 15, 2008. The warrants will have the following exercise prices: (i) the first 10,083,333 warrants will have an exercise price of \$0.20; (ii) the next 10,083,333 warrants will have an exercise price of \$0.29; and (iii) the final 10,083,334 warrants will have an exercise price of \$0.36. Because of our recent resolution and restructuring of the amounts owed by us to Ramot under the Ramot license agreement, ACCBT elected to accelerate the date of the first closing under the subscription agreement from August 30, 2007 to August 20, 2007. Therefore, on August 20, 2007, we received an aggregate of \$1,000,000 from ACCBT and in exchange we issued to ACCBT an aggregate of 6,875,000 shares of common stock and a warrant to purchase an aggregate of 7,562,500 shares of common stock.

Moreover, in July 2007, we entered into a letter agreement with Double U Master Fund L.P. pursuant to which we agreed to issue to Double U an aggregate of 630,000 shares of common stock upon exercise of a common stock purchase warrant dated as of October 3, 2006 held by Double U. In lieu of paying the purchase price for the shares in cash, Double U agreed to waive the repayment of the promissory note we issued to Double U on February 1, 2006 in the principal amount of \$189,000, except for accrued interest of \$17,340. Upon payment of the accrued interest and issuance of the 630,000 shares to Double U, all of our obligations owed to Double U under the February 1, 2006 note and the common stock purchase warrant were satisfied in full.

In addition, the restructuring of our obligations to Ramot eliminated significant risks that were faced by the Company.

In order to execute our business plan, we will need to raise additional capital. If we are unable to raise additional capital on favorable terms and in a timely manner, we will not be able to execute our business plan and we could be forced to restrict or cease our operations. We will need to raise additional funds to meet our anticipated expenses so that we can execute our business plan. We expect to incur substantial and increasing net losses for the foreseeable future as we increase our spending to execute our development programs. Our auditors have expressed in their audit report that there is substantial doubt regarding our ability to continue as a going concern.

If we satisfy the closing conditions contained in the subscription agreement with ACCBT, then we expect to issue and sell additional shares and warrants to ACCBT through November 2008 for aggregate consideration of up to \$5,000,000. However, if we do not satisfy the closing conditions contained in the subscription agreement, and if ACCBT does not elect to purchase additional shares and warrants, we will need to seek additional financings to allow us to execute our business plan. Even if ACCBT purchases all of the shares and warrants under the subscription agreement, we will still need to secure additional funds to effect our plan of operations. We may not be able to raise additional funds on favorable terms, or at all. If we are unable to obtain additional funds on favorable terms and in a timely fashion, we will be unable to execute our business plan and we will be forced to restrict or cease our operations.

Assuming we raise additional funds through the issuance of equity, equity-related or debt securities, these securities may have rights, preferences or privileges (including registrations rights) senior to those of the rights of our common stock and our stockholders will experience additional dilution.

Your percentage ownership will be diluted by future offerings of our securities, upon the conversion of outstanding convertible promissory notes into shares of common stock and by options, warrants or shares we grant to management, employees, directors and consultants. If we issue all of the shares and warrants to ACCBT Corp. as provided for in the subscription agreement, it will have a significant dilutive effect on your percentage ownership in the Company. In addition, in order to meet our financing needs described above, we may issue additional significant amounts of our common stock and warrants to purchase shares of our common stock. The precise terms of any future financings will be determined by us and potential investors and such future financings may also significantly dilute your percentage ownership in the Company.

In November 2004 and February 2005, our Board of Directors adopted and ratified the 2004 Global Share Option Plan and the 2005 U.S. Stock Option Plan and Incentive Plan (the "Global Plan" and "U.S. Plan" respectively and the "Plans" together), and further approved the reservation of 9,143,462 shares of our common stock for issuance under the Plans (the "Shares"). Our shareholders approved the Plans and the issuance of the Shares in a special meeting of shareholders that was held on March 28, 2005. We have made and intend to make further option grants under the Plans or otherwise issue warrants or shares of our common stock to individuals under the Plans. For example, as of August 3, 2007:

- under our Global Plan, we have granted and not canceled a total of 5,251,778 options with various exercise prices and expiration dates, to officers, directors, services providers, consultants and employees.
- under our U.S. Plan we have issued an additional 1,730,000 shares of restricted stock and options for grants to Scientific Advisory Board members, service providers, consultants and directors.

Such issuances will, if and when made (and if options or warrants are subsequently exercised), dilute your percentage ownership in the Company.

As of August 3, 2007, we have issued convertible notes that have not yet been converted in an aggregate principal amount of \$1,930,000 to various investors. Each holder of a convertible note may choose to convert all or part of the outstanding principal and interest amount of such holder's note into shares of our common stock on or prior to the maturity date of the respective note. The maximum number of shares, in the aggregate, that are issuable pursuant to outstanding convertible notes is 83,400,000.

As of August 3, 2007, we have issued 6,329,066 shares to investors, directors, service providers and consultants. When we register the shares or those underlying convertible securities for which we have undertaken to register, they can be sold in the public market. In addition, the shares that we will not register will become eligible for sale into the public market subject to and in accordance with applicable SEC rules and regulations, which provide exemptions from registration requirements. If any of the holders of these shares or convertible securities, or any of our existing stockholders, sell a large number of shares of our common stock, or the public market perceives that existing stockholders might sell shares of our common stock, the market price of our common stock could decline significantly.

Item 3. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our President and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")). Based on this evaluation, our President and Chief Financial Officer concluded that our disclosure controls and procedures are effective, as of the end of the period covered by this report, to ensure that information required to be disclosed by us in the reports we file under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that the information required to be disclosed by us in such reports is accumulated and communicated to our management, including our President and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the fiscal quarter to which this report relates that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II: OTHER INFORMATION

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

On May 6, 2007, we issued a warrant to purchase 250,000 shares of common stock at an exercise price of \$0.45 per share to ACCBT Corp.

On July 3, 2007, we issued a warrant to purchase 30,000 shares of common stock at an exercise price of \$0.45 per share to Yehoshua Rabinowitz.

On July 3, 2007, we issued a warrant to purchase 100,000 shares of common stock at an exercise price of \$0.45 per share to Meir Rosenbaum.

On August 10, 2007, we issued an aggregate of 630,000 shares of common stock to Double U Fund for a purchase price of \$0.30 per share upon exercise of a warrant.

On August 10, 2007, we issued an aggregate of 97,696 shares to Double U Fund upon cashless exercise of a warrant.

On August 10, 2007, we issued 6,875,000 shares of common stock to ACCBT Corp. for an aggregate purchase price of \$1,250,000, of which \$250,000 was paid upon conversion by ACCBT Corp. of the \$250,000 8% Convertible Promissory Note dated May 6, 2007.

On August 10, 2007, we issued a warrant to purchase 7,562,500 shares of common stock at an exercise price of \$0.20 per share to ACCBT Corp.

These transactions did not involve any underwriters, underwriting discounts or commissions and we believe that this transaction was exempt from the registration requirements of the Securities Act of 1933 pursuant to Section 4(2) thereof and Regulation D promulgated thereunder. The Company plans to use any proceeds from such securities issuances or warrant exercises for general corporate and working capital purposes.

Item 5. Other Information

During the quarters ended April 30, 2007 and June 30, 2007, we made no material changes to the procedures by which shareholders may recommend nominees to our Board of Directors, as described in our most recent proxy statement.

Item 6. Exhibits.

The Exhibits listed in the Exhibit Index immediately preceding such Exhibits are filed with or incorporated by reference in this report.

37

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BRAINSTORM CELL THERAPEUTICS INC.

August 20, 2007

By:

/s/ Chaim Lebovits

Name: Chaim Lebovits

Title: President (Principal Executive Officer)

August 20, 2007

By:

/s/ David Stolick

Name: David Stolick

Title: Chief Financial Officer (Principal
Financial and Accounting Officer)

EXHIBIT INDEX

Exhibit Number	Description
10.1	Subscription Agreement, dated July 2, 2007, by and between the Company and ACCBT Corp. is incorporated herein by reference to Exhibit 10.1 of the Company's Current Report on Form 8-K filed on July 5, 2007 (File No. 333-61610).
10.2	Form of Common Stock Purchase Warrant to be issued by the Company to ACCBT Corp. is incorporated herein by reference to Exhibit 10.2 of the Company's Current Report on Form 8-K filed on July 5, 2007 (File No. 333-61610).
10.3	Form of Registration Rights Agreement to be entered into by the Company and ACCBT Corp. is incorporated herein by reference to Exhibit 10.3 of the Company's Current Report on Form 8-K filed on July 5, 2007 (File No. 333-61610).
10.4	Second Amended and Restated Research and License Agreement, dated July 31, 2007, by and between the Company and Ramot at Tel Aviv University Ltd.
10.5	Second Amended and Restated Registration Rights Agreement, dated August 1, 2007, by and between the Company and Ramot at Tel Aviv University Ltd.
10.6	Waiver and Release, dated August 1, 2007, executed by Ramot at Tel Aviv University Ltd. in favor of the Company.
10.7	8% Convertible Promissory Note, dated May 6, 2007, in the principal amount of \$250,000 issued by the Company to ACCBT Corp. is incorporated herein by reference to Exhibit 10.1 of the Company's Current Report on Form 8-K filed on May 10, 2007 (File No. 333-61610).
10.8	Common Stock Purchase Warrant, dated May 6, 2007, issued by the Company to ACCBT Corp. is incorporated herein by reference to Exhibit 10.2 of the Company's Current Report on Form 8-K filed on May 10, 2007 (File No. 333-61610).
31.1	Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification of the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	Certification of the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.